大剂量阿糖胞苷治疗儿童急性髓系白血病的耐受性研究  

The Dose Tolerance Research of High-dose Cytarabine in the Treatment of Children with Acute Myeloid Leukemia

作　　者：卫凤桂[1] 孟冬梅[2] 吴丽萍[1] 吴泽霖[1] 曾意茹[1] 陈福雄[1] 

机构地区：[1]广州医学院第一附属医院小儿血液肿瘤研究室,广东广州510120 [2]广州医学院第一附属医院药剂科,广东广州510120

出　　处：《现代生物医学进展》2013年第21期4119-4121,共3页Progress in Modern Biomedicine

基　　金：广州市医药卫生科技项目(编号20121A011136)

摘　　要：目的:探讨儿童急性髓系白血病对于大剂量阿糖胞苷的耐受性,为临床用药提供指导。方法:从我院2007年1月～2011年1月收治的儿童急性髓系白血病患者中选取40例,将其作为临床研究对象,随机分成A、B两组,每组均20例患者。两组都给予大剂量阿糖胞苷,A组患者给予体表面积3 g/m2用量;B组患者给予体表面积2 g/m2用量。一周后,分别观察两组急性髓系白血病儿童的治疗效果、神经系统毒性和副作用。结果:治疗一周后,A组患者贫血例数2例(10.00%)较B组患者贫血例数8例(40.00%)少,A组患者所表现的神经毒性头疼、嗜睡、淡漠及惊厥方面较B组患者严重,A组患者所表现的副作用眼球震颤、轮替运动障碍、共济失调均较B组患者严重。结论:大剂量阿糖胞苷虽具有更好的疗效,基本耐受但其不良反应相对严重。Objective： To investigate the tolerance of children acute myeloid leukemia to high-dose cytarabine,so as to provide guidance for clinic.Methods： 40 cases of acute myeloid leukemia patients admitted from January 2007 to January 2011 were selected as the clinical study objects,and randomly divided into group A and group B,each group of 20 patients.The two groups were given high-dose cytarabine.Patients of group A were given dosage of 3 g/m2body surface area;group B were given dosage of 2 g/m2body surface area.A week later observed was the therapeutic effect,nervous system toxicity and side effects of the two groups.Results： After one week of treatment,2 cases in group A（10.00%） had anemia,less than that in group B which had 8 cases of anemia（40.00%）.Patients in group A showed severer degree in neurotoxic headache,lethargy,apathy and convulsions than in group B,as well as in aspects of nystagmus,dysdiadochokinesia and ataxia.Conclusion： High-dose of cytarabine has better efficacy and were generally tolerated,but resulted in severe adverse reactions.

关 键 词：大剂量 阿糖胞苷 急型髓性白血病 耐受 

分 类 号：R733.717[医药卫生—肿瘤]